Commentary: Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy - Takeaways - MDSpire

Analysis of Acute and Long-Term Toxicity in Prostate Cancer Patients Undergoing Moderately Versus Ultra-Hypofractionated Radiotherapy

  • By

  • Toufic Eid

  • Tarek Al-Bitar

  • Osama Mohamad

  • July 20, 2026

Share

  • 1

    Cifuentes-Quin et al. compared toxicity in prostate cancer patients treated with moderately and ultra-hypofractionated radiotherapy.

  • 2

    The study involved 229 patients and highlighted the limited real-world data from Latin America regarding prostate cancer treatment.

  • 3

    Acute toxicity rates reported for UHRT were significantly lower than those from the PACE-C trial, raising questions about the findings.

  • 4

    The study's multivariable analysis excluded fractionation schedule, complicating the interpretation of late toxicity results.

  • 5

    Differences in baseline urinary medication use and sample size asymmetry between groups may affect the study's conclusions.

Original Source(s)

Commentary: Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy

  • by Toufic Eid, Tarek Al-Bitar, Osama Mohamad

  • July 20, 2026

Related Content

Prevalence of thyroid disorders in inland and coastal populations: A systematic review

Prognostic significance of tumoral Siglec-15 expression in solid tumors: a systematic review and meta-analysis

Association between preoperative neutrophil percentage-to-albumin ratio and survival outcomes in patients with colorectal cancer undergoing radical surgery: a retrospective study with external validation